Abstracts tagged "juvenile idiopathic arthritis (JIA) and meta-analysis"

Abstract Number: 2165 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologic Agents In Patients With Poly-Articular Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Controlled Withdrawal Trials
Gil Amarilyo¹, Simon Tarp², Ivan Foeldvari³, Neta Cohen⁴, Tracy D. Pope⁵, Jennifer M.P. Woo⁶, Robin Christensen² and Daniel Furst⁵, ¹Dana-Dwek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ³Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁴Dana-Duek Children's hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵David Geffen School of Medicine, University of California, Los Angeles, CA, ⁶Pediatric Rheumatology, Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Although various biologic agents (BAs) are in use for polyarticular juvenile idiopathic arthritis (pJIA), a combined meta-analytic summary comparing the efficacy and safety among…
Abstract Number: 1142 • 2012 ACR/ARHP Annual Meeting
Efficacy of Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review Using Indirect Comparisons
Janneke Anink¹, Marieke H. Otten¹, Sandra Spronk² and Lisette W.A. Van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Department of Epidemiology and Radiology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: During the last decade the availability of biologic agents for the treatment of juvenile idiopathic arthritis (JIA) increased substantially. Because direct head-to-head trials comparing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].